Abstract
As the use of immune checkpoint inhibitors (ICIs) expands in oncology, clinicians are encountering a wider array of immune-related adverse events (irAEs). While single-organ inflammation is common, concurrent multi-organ involvement is rare and presents significant diagnostic challenges. This report details a unique case of a patient in his 80s who developed simultaneous hepatitis, cholangitis, and pancreatitis following pembrolizumab therapy for renal pelvic cancer. The case highlights the importance of recognizing multi-organ irAE patterns on imaging to ensure timely diagnosis and management.
Introduction
Immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the immune system's ability to target malignant cells. However, this systemic activation can lead to "friendly fire" in the form of immune-related adverse events (irAEs). While irAEs commonly affect the skin, colon, or lungs, simultaneous inflammation of the liver, bile ducts, and pancreas is exceptionally rare. This "triple threat" of digestive organ inflammation can mimic other autoimmune conditions or infections, potentially leading to delayed treatment.
Case Presentation
A man in his 80s, undergoing pembrolizumab treatment for recurrent renal pelvic cancer, presented with a loss of appetite. Initial laboratory results showed significant elevations in inflammatory markers and liver enzymes (AST: 942 IU/L, ALP: 2081 IU/L). Pancreatic enzymes were also elevated (Amylase: 528 IU/L).
Initial non-contrast CT suggested cholecystitis and cholangitis. However, when symptoms failed to improve with antibiotics, advanced imaging was performed to reassess the underlying cause.
Diagnostic Findings
Contrast-enhanced dynamic CT and gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid-enhanced MRI (EOB-MRI) provided critical insights. The imaging revealed not only bile duct wall thickening and edematous changes along Glisson's sheath—suggestive of cholangitis—but also inflammatory enlargement in the pancreatic tail.
A liver biopsy was performed to confirm the diagnosis. Histopathological analysis showed significant T-cell infiltration, specifically CD3(+) cells with a predominance of CD8(+) "killer" T cells, confirming that the inflammation was a direct result of the ICI's effect on T-cell regulation. This led to a final diagnosis of concurrent hepatitis, cholangitis, and pancreatitis as irAEs.
Discussion
The imaging findings for irAE cholangitis often mimic primary sclerosing cholangitis (PSC) or IgG4-related cholangitis. However, the simultaneous presence of pancreatitis in a patient receiving immunotherapy should strongly point toward an irAE.
A key clinical takeaway from this case is the differential response to treatment. While irAE hepatitis typically responds well to corticosteroids, irAE cholangitis is notably more resistant, with literature suggesting a steroid response rate of only approximately 11.5%. In this patient, high-dose prednisolone (60 mg/day) successfully normalized enzyme levels and resolved the imaging abnormalities, though the patient eventually succumbed to the progression of his primary cancer nine months later.
Conclusion
This case underscores the necessity for clinicians to maintain a high index of suspicion for multi-organ irAEs in patients treated with ICIs. Recognizing the imaging "signature" of concurrent bile duct and pancreatic inflammation can be the clue needed to distinguish irAEs from more common biliary conditions. Early identification and the initiation of immunosuppressive therapy are vital to managing these complex systemic responses.
Summary updated